This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Zymergen Inc.
3/22/2022
Good day, and thank you for standing by, and welcome to Zymer's and fourth quarter 2021 financial results call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. If asked a question during the session, you'll need to press star 1 on your telephone. Please be advised this call is being recorded. If you require any further assistance, please press star 0. I would now like to hand the conference over to your host today, Mike Dooland, Director of Communications. You may begin.
Good afternoon. Earlier today, Zymergen released preliminary financial results for the quarter and full year ending December 31st, 2021. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to investors at zymergen.com. Joining me today from Zymergen are Jay Flatley, Acting Chief Executive Officer, and Ina Singh, Chief Financial Officer. Before we begin, I would like to remind you that management will make statements during this call that are forward-looking statements within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release Zymergen issued today. For a more complete list and description, please see the risk factors section of the company's latest 10Q and other filings with the Securities and Exchange Commission, including, when filed, the Form 10-K for 2021. Except as required by law, Zymergen disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, March 22nd, 2022. In addition, please note that the fourth quarter and full year financial results discussed today are preliminary and estimated and are subject to the completion and finalization of Zymergen's financial and accounting closing procedures. With that, I'll turn the call over to Jay.
Thanks, Mike, and good afternoon, everyone. On today's call, I will begin with an update on progress across our program pipeline, then review recent developments from our research team, and end with a few milestones you can use to monitor our progress. Ina will also share a more detailed review of our financials, including our preliminary fourth quarter and full year 2021 results and our forecasted cash burn. After a lot of hard work by our teams, we exited 2021 with a clear focus on who we are and what we do. Zymergen is a biotech company that designs and produces molecules, microbes, and materials for diverse end markets. Our three-year strategic plan was approved by our board in February. This plan outlines our core areas of focus, as well as the strategies and tactics to build our business. At the recent JP Morgan conference, I discussed the nine strategic imperatives that provide the bedrock for this plan. We are prioritizing three business areas. advanced materials, drug discovery, and automation. In advanced materials, we're focused on four end markets, agriculture, water repellency, advanced polymers, and enzymes for healthcare. In agriculture, our initial program in nitrogen fixation is delivering evolved microbes to a partner to replace nitrogen fertilizer. It's believed that microbes can meet all of corn's nitrogen needs and ultimately be expanded to include other cereal crops and nutrients. Our partner is preparing the Gen 2 strain consortium to plant in this year's field trials, and we're already hard at work on the Gen 3 consortium for 2023 trials. Our water repellency work is focused on a family of molecules that adhere to cellulose and repel water. We are currently making a prototype paper that is being tested by potential partners for various applications, including drinking straws. And early tests have indicated excellent water repellency and wet tensile strength. which has the potential to reduce the number of plies required. We think this technology is extensible to other substrates, which may broaden the application to markets where paper is replaced in plastics or new market segments such as clothing. In advanced polymers, we believe we found an important adjacent market opportunity to use our Z2 polymer in high-performance 3D printing applications. As you will recall, Z2 was the base material for Hylink. This polymer has critical advantages for printing parts that require high tensile strength and improved yield, showing approximately twice the strength compared to incumbents. We have ongoing tests with 3D printing OEMs who supply the devices and consumables and with end users in defense and aerospace. We also have interest in development grade material being used for validation and qualification, the results of which will inform any future commercialization decisions. The other active program in our advanced polymer portfolio is our partnership with Sumitomo, which is currently focused on applications for electronics. As a reminder, Sumitomo is exploring the use of Z1 as a cover film on phones. They will be the single point of commercialization and are sharing equally in development costs. This program team recently ran a successful 3,000-liter fermentation to provide evaluation material, and the resulting product had a purity of greater than 99%. Finally, some updates on our enzyme program, which is initially focused on two components that are critical to produce mRNA vaccines, namely VCE and 2-OMT. The global market for enzymatic capping that supports this production is approximately $800 million in 2022. And although supply is largely caught up with demand, the supply chains are not yet resilient. Our excitement about this market is based on the potential of post-COVID mRNA therapeutics and vaccines. We've decided to retain responsibility for manufacturing these enzymes using outside contractors, which we believe will help improve margins in a competitive market. Discussions are underway with multiple commercial partners, and we expect to start sampling materials soon. Moving on to drug discovery, our program leverages our metagenomic database, which provides access to natural product diversity at an unprecedented scale. Our powerful machine learning tools allow us to uncover molecular matter that inhibits targets of interest, focused initially in oncology, where we think our platform has unique advantages and the market has a consistent record of valuing innovation. We're active with leading biopharma companies, exploring our database against their targets of interest, and are in discussions with multiple potential partners to take programs forward. In October of 2021, we received a grant from the Bill and Melinda Gates Foundation to use our technology to explore 11 high-potential therapeutic targets across malaria, tuberculosis, and COVID-19. Earlier this month, we announced progress to the first three targets, having identified over 200 hits for APP that performed better than the benchmark molecule, Avstatin. We are now moving APP for malaria into validation testing, and PLPro for COVID-19 is likely to follow. Infectious disease is not a targeted area of interest for our internal programs, but this work proves the power of our drug discovery platform and can enable third parties to move these and other hits forward for continued development. And finally, turning to automation, we're now offering our technology to customers outside the company that are interested in improving the throughput efficiency and reliability of their lab operations. We have over 20 potential customers in our commercial pipeline, and have signed two contracts for system design. While these initial contracts are small, creating a detailed design for a customer can greatly increase the probability of a future sale. To support our business, we've implemented a rigorous product development program, which evaluates programs through stringent phase gates designed to verify all aspects of the market, the product, and the team resources to fully develop that product to loan. This is fully implemented and there are six product programs currently in the pipeline. If all of these programs proceed without delay or cancellation, we expect to have at least three of these programs in the pilot phase and one in the launch phase by the end of 2022. Ahead of the process, we have a robust research engine to create a pipeline of new opportunities. I recently visited members of our research team in Cambridge, Massachusetts, where we were shown over 20 new material innovations that range from oxygen and moisture barriers for food containers to water repellent fabrics to seed coatings. These exciting projects are early proofs of concept and will require considerable market review and technology vetting before they're qualified to enter our pipeline. However, they demonstrate our research team's ability to quickly move from idea to working material. In fact, this research cycle happened in less than four months. This approach allows us to gather feedback from stakeholders or even potential customers to make faster, smarter decisions about which programs to advance. As I shared during my recent presentation at the Cowan Healthcare Conference, our goal for the research team is to move five programs into what we call the waiting room by the end of 2022, ready for entry into our pipeline when resources allow. We expect to put two to four of those into product development by year end. I'll wrap up this portion of my remarks with a brief summary of next steps for each business. In automation, we believe there's a potential to sign commercial contracts during 2022. However, these are unlikely to generate revenue this year because we will need to configure these systems, order material, build and test our modular components, install them, and qualify them before we book revenue. In drug discovery, we're looking for one potential partnership before year end and obviously hopeful for more in 2023. And lastly, in advanced materials, our 2022 goal is to complete distribution partnerships in both enzymes and 3D printing, which would provide both a channel to market and also validation of the technology. As we've stated in earlier presentations, we do not expect meaningful revenue in the advanced materials programs this year. With that, I'll turn it over to Ina to update you on our financials.
You're reading a preview of the ZY Q4 2021 earnings call.
Free account.